FAQ/Help |
Calendar |
Search |
Today's Posts |
08-17-2014, 11:49 PM | #1 | ||
|
|||
Member
|
http://www.lctglobal.com/upload/news...%20implant.pdf
Successful second implant of NTCELL for Parkinson’s 18 August 2014 – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL ® for Parkinson’s disease. LCT plans to complete the patient treatment phase of the study this year. The Phase I/IIa clinical trial is an open-label investigation of the safety and clinical effects of NTCELL in patients who can no longer respond to current therapy. The trial is directed by Dr Barry Snow MBChB, FRACP, FRCPC, an internationally recognised clinician and researcher in Parkinson’s disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board. Dr Ken Taylor, CEO of LCT says, “A great deal of hard work, preclinical research and scientific endeavour has gone into the discovery and developm ent of NTCELL. Our innovative approach is the first to target regeneration of brain cells for patients who are failing the current conventional treatment for Parkinson’s disease.” – Ends – For further information: www.lctglobal.com At the company: Ken Taylor Chief Executive Tel: +64 9 276 2690 Mobile: +64 21 796000 ktaylor@lctglobal.com Media enquires: Rachael Joel Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 403 504 rachaelj@botica.co.nz About Living Cell Technologies Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL ® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration. NTCELL is in Phase I/IIa clinical trial in New Zealan d for the treatment of Parkinson’s disease. It has the potential to be used in a number of othe r central nervous system indications such as Huntington’s, Alzheimer’s and motor neurone diseases. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
NTCELL LCT Parkinson’s trial resumes patient recruitment | Parkinson's Disease | |||
Successful trial and awaiting permanent implant | SCS & Pain Pumps | |||
Neurologix Announces Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease | Parkinson's Disease | |||
lithium salts new successful againt Parkinson | Parkinson's Disease | |||
PRE-CLINICAL STUDY: Implant patient's own retinal cells to treat Parkinson's disease | Parkinson's Disease Clinical Trials |